丙氨酸布立尼布是一種ATP競爭性的 VEGFR2 抑制劑，IC50 值為 25 nM；可以適度抑制 VEGFR1 和 FGFR1，對 VEGFR2 的選擇性是對 PDGFRβ的 240 倍，是一種用于口服給藥的研究性抗腫瘤藥物，用于治療肝細胞癌或肝癌（也稱為惡性肝癌），最常見的肝癌。
(R)-1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)propan-2-ol
Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate
1-(2-Fluoro-3-methoxy-6-nitrophenyl)propan-2-one
1-(2,3-Difluoro-6-nitrophenyl)propan-2-one
6-(Benzyloxy)-4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine
6-(Benzyloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one
4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol
Ethyl 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate
2-(4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)propan-2-ol
